China Medical Materials Association released the "2013 China Medical Device Blue Book", Chen Hongyan, Secretary General of the Medical Devices Branch of China Medical Materials Association, said that this is the first blue book released by China's medical device industry. The book predicts that the total import and export volume of Chinese medical devices will reach 33 billion U.S. dollars, and pointed out that the price of imported medical equipment is generally higher than 50%-100% of the country of origin such as Europe, America and Japan, such as TOMO radiotherapy system and other equipment, in Europe, America, etc. The country is mostly 2.5 million US dollars, and China's imports are more than 5 million US dollars.

Medical equipment is 15 years behind international.

The procurement of some imported equipment is mainly based on government investment, which increases the financial burden. Not only that, but more serious is that the after-sales and maintenance of imported equipment are carried out by the original company's specialized personnel. Once the maintenance delays due to some reasons, the supply of consumables is interrupted, the use of equipment will be embarrassed. In addition, the core technology of high-end medical equipment is in the hands of foreign companies, and information security such as medical diagnosis, treatment data and patient medical files are also facing great risks.

The industry believes that in the global medical technology and biomedical maps, China is not the most productive drug, but the Chinese medicine and the medical equipment that spontaneously form certain advantages. However, the "Blue Book" pointed out that the gap between the overall level of China's medical devices and the international advanced level is about 15 years. Domestic high-end medical devices mainly rely on imports, and the import value accounts for about 40% of the total market. The import companies are mainly internationally renowned companies. About 80% of the CT market, 90% of the ultrasonic instrument market, 85% of the test instrument market, 90% of the magnetic resonance equipment, 90% of the electrocardiograph market, 80% of the high-end monitor market, 90% of the high-end physiological records The instrument market and 60% of the sleep charter market are occupied by foreign brands. The focus of competition among multinational enterprises is design concept, product quality and after-sales service. High-quality products are favored by large domestic hospitals. Therefore, foreign products are sold to large domestic hospitals, especially the top three hospitals.

35% of products are exported to domestic sales.

In the first half of the year, China imported medical equipment from 89 countries and regions. About 35% of the products in the import and export data or their main components are produced in China, first exported to foreign countries, and then imported to China for sales. From the perspective of the import region, Europe is China's largest source of medical device imports, North America is the second largest source of imports, Asia ranks third, and imports from the three continents account for a total of 97.57%. From the specific importing countries and regions, the top ten are the United States, Germany, Japan, Switzerland, South Korea, Ireland, the United Kingdom, France, the Netherlands and Singapore. The total import value reached US$5.71 billion, accounting for a total of 83.86. %.

These data show that China's medical device industry chain is dominated by foreign multinational companies in the high-end value chain, and many key technologies are still monopolized by large companies in developed countries. Domestic companies only occupy a portion of the low-end value chain. There are a few domestic enterprises that enter the high-end product market, and often cannot form a R&D team with independent innovation capabilities. By the end of 2012, the scale of China's medical device manufacturing enterprises has reached 177,788, and about 90% of medical device manufacturers are small and medium-sized enterprises with low annual production income of less than one or two million. There are not many companies that produce electronic monitoring equipment, ultrasonic diagnostic equipment, X-ray tomography equipment, CT and other high-tech products with their own brands and whose income exceeds 500 million yuan.

Chinese companies lack strategic innovation.

The "Blue Book" pointed out that domestic enterprises are struggling for the meager profits of the low-end market, while the foreign medical equipment giants occupying the high-end market are unique in the scenery. The root of this strong contrast lies in the domestic medical device market. Lack of strategic planning and integration, can not form a R & D team with independent innovation capabilities.